Thrombin activation and liver inflammation in advanced hepatitis C virus infection

World Journal of Gastroenterology

Volumn 22, Issue 18, 2016, Pages 4427-4437

  González Reimers, Emilio ^a   Quintero Platt, Geraldine ^a   Martín González, Candelaria ^a   Pérez Hernández, Onán ^a   Romero Acevedo, Lucía ^a   Santolaria Fernández, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Coagulation; Fibrogenesis; Hepatitis C virus; Liver cirrhosis; Parenchymal extinction; Portal thrombosis; Protein C

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; END STAGE LIVER DISEASE; ENZYME ACTIVATION; FIBRINOLYSIS; FIBROGENESIS; HEMOSTASIS; HEPATITIS C; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MICROCIRCULATION; NONHUMAN; PORTAL VEIN; PREVALENCE; RISK ASSESSMENT; STELLATE CELL; THROMBOCYTE AGGREGATION; THROMBOSIS; ANIMAL; BLOOD; COMPLICATION; DISEASE COURSE; HEPACIVIRUS; HEPATIC STELLATE CELL; HEPATITIS C, CHRONIC; LIVER; METABOLISM; PATHOGENICITY; PATHOLOGY; RISK FACTOR; THROMBOCYTE; VENOUS THROMBOSIS; VIROLOGY;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; DISEASE PROGRESSION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATIC STELLATE CELLS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS; PLATELET AGGREGATION; PORTAL VEIN; RISK FACTORS; THROMBIN; VENOUS THROMBOSIS;

EID: 84970950194     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i18.4427     Document Type: Article

References (94)

1. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. Br J Haematol 2013; 162: 819-826 [PMID: 23841464 DOI: 10.1111/bjh.12462]
2. Hepner M, Karlaftis V. Antithrombin. Methods Mol Biol 2013; 992: 355-364 [PMID: 23546728 DOI: 10.1007/978-1-62703-339-8 _28]
3. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost 2016; 115: 712-728 [PMID: 26676884 DOI: 10.1160/ TH15-08-0687]
4. Sheffield WP, Bhakta V. The M358R variant of a1-proteinase inhibitor inhibits coagulation factor VIIa. Biochem Biophys Res Commun 2016; 470: 710-713 [PMID: 26797521 DOI: 10.1016/ j.bbrc.2016.01.069]
5. Mast AE. Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein. Arterioscler Thromb Vasc Biol 2016; 36: 9-14 [PMID: 26603155 DOI: 10.1161/ATVBAHA.115.305996]
6. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11 Suppl 1: 11-23 [PMID: 23809107 DOI: 10.1111/jth.12221]
7. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003; 33: 375-381 [PMID: 15692247]
8. Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, Sangro B. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996; 23: 199-204 [PMID: 8591841 DOI: 10.1002/hep.510230201]
9. Biron C, Andréani H, Blanc P, Ramos J, Ducos J, Guigue N, Michel H, Larrey D, Schved JF. Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med 1998; 131: 243-250 [PMID: 9523848 DOI: 10.1016/S0022-2143(98)90096-8]
10. Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014; 31: 891-903 [PMID: 25047758 DOI: 10.1007/ s12325-014-0138-4]
11. Wang CC, Chang CT, Lin CL, Lin IC, Kao CH. Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis: A Population-Based Cohort Study. Medicine (Baltimore) 2015; 94: e1585 [PMID: 26402820 DOI: 10.1097/ MD.0000000000001585]
12. Chen HS, Xing SR, Xu WG, Yang F, Qi XL, Wang LM, Yang CQ. Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors. Exp Ther Med 2013; 5: 819-824 [PMID: 23403613 DOI: 10.3892/etm.2013.918]
13. Harada M, Fujisawa Y, Sakisaka S, Kawaguchi T, Taniguchi E, Sakamoto M, Sumie S, Sasatomi K, Koga H, Torimura T, Ueno T, Gondo K, Yoshida H, Tanikawa K, Sata M. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol 2000; 35: 272-277 [PMID: 10777156]
14. Ordi-Ros J, Villarreal J, Monegal F, Sauleda S, Esteban I, Vilardell M. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol 2000; 7: 241-244 [PMID: 10702499]
15. Violi F, Ferro D, Basili S, Artini M, Valesini G, Levrero M, Cordova C. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med 1995; 43: 550-554 [PMID: 8605614]
16. Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol 2014; 2: 234-239 [PMID: 26357629 DOI: 10.14218/JCTH.2014.00031]
17. Toschi V, Fiorini GF, Motta A, Renoldi P, Paracchini ML, Gibelli A. Clinical significance of endothelial damage markers in essential mixed cryoglobulinemia. Acta Haematol 1991; 86: 90-94 [PMID: 1950376]
18. Pircher J, Czermak T, Merkle M, Mannell H, Krötz F, Ribeiro A, Vielhauer V, Nadjiri J, Gaitzsch E, Niemeyer M, Porubsky S, Gröne HJ, Wörnle M. Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFa receptor subtype 2. PLoS One 2014; 9: e113351 [PMID: 25419735 DOI: 10.1371/journal.pone.0113351]
19. Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, Franitza S, Weiss I, Avniel S, Boaz P, Hanna J, Zamir G, Eid A, Mandelboim O, Spengler U, Galun E, Peled A. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34: 1164-1174 [PMID: 15048728 DOI: 10.1002/ eji.200324441]
20. Falasca K, Mancino P, Ucciferri C, Dalessandro M, Zingariello P, Lattanzio FM, Petrarca C, Martinotti S, Pizzigallo E, Conti P, Vecchiet J. Inflammatory cytokines and S-100b protein in patients with hepatitis C infection and cryoglobulinemias. Clin Invest Med 2007; 30: E167-E176 [PMID: 17892758]
21. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972 [PMID: 10980636]
22. Ishii H, Horie S, Kizaki K, Kazama M. Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood 1992; 80: 2556-2562 [PMID: 1330076]
23. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissuetype plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-5803 [PMID: 3128548]
24. Hodowanec AC, Lee RD, Brady KE, Gao W, Kincaid S, Plants J, Bahk M, Mackman N, Landay AL, Huhn GD. A matched crosssectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis 2015; 15: 190 [PMID: 25884329 DOI: 10.1186/s12879-015-0920-1]
25. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-350 [PMID: 12851650 DOI: 10.1038/sj.mn.7800198]
26. Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, Van Geet C, Cassiman D. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008; 27: 1017-1029 [PMID: 18331464 DOI: 10.1111/j.1365-2036.2008.03674.x]
27. Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J, Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology 2001; 48: 818-822 [PMID: 11462931]
28. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541 [PMID: 12905138 DOI: 10.1086/376971]
29. Tana MM, Zhao X, Bradshaw A, Moon MS, Page S, Turner T, Rivera E, Kleiner DE, Heller T. Factors associated with the platelet count in patients with chronic hepatitis C. Thromb Res 2015; 135: 823-828 [PMID: 25728497 DOI: 10.1016/j.thromres.2015.02.010]
30. Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007; 26 Suppl 1: 13-19 [PMID: 17958515 DOI: 10.1111/j.1365-2036.2007.03512.x]
31. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 2001; 68: 202-209 [PMID: 11754404 DOI: 10.1002/ajh.1180]
32. Español I, Gallego A, Enríquez J, Rabella N, Lerma E, Hernández A, Pujol-Moix N. Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. Hepatogastroenterology 2000; 47: 1404-1406 [PMID: 11100362]
33. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, Ragone E, Durante Mangoni E, Ruggiero G. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 590-595 [PMID: 11380442]
34. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podestà E, Romagnoli P, Testa E, Chiarbonello B, Polegato S, Mamone M, Testa R. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002; 37: 572-577 [PMID: 12399221]
35. Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 44: 754-758 [PMID: 10205219]
36. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100: 1311-1316 [PMID: 15929762]
37. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24: 135-140 [PMID: 8907565]
38. Panzer S, Seel E, Brunner M, Körmöczi GF, Schmid M, Ferenci P, Peck-Radosavljevic M. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77: 513-517 [PMID: 17042765]
39. Olariu M, Olariu C, Olteanu D. Thrombocytopenia in chronic hepatitis C. J Gastrointestin Liver Dis 2010; 19: 381-385 [PMID: 21188328]
40. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014; 20: 7312-7324 [PMID: 24966602 DOI: 10.3748/wjg.v20.i23.7312]
41. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156 [PMID: 21751907 DOI: 10.1056/NEJMra1011170]
42. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012-3017 [PMID: 18443906 DOI: 10.1007/s10620-008-0265-3]
43. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V. [Venous thromboembolism and liver cirrhosis]. Rev Esp Enferm Dig 2008; 100: 259-262 [PMID: 18662076 DOI: 10.4321/ S1130-01082008000500002]
44. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31: 366-374 [PMID: 19863496 DOI: 10.1111/j.1365-2036.2009.04182.x]
45. Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World J Gastroenterol 2014; 20: 5737-5745 [PMID: 24914335 DOI: 10.3748/wjg.v20.i19.5737]
46. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558 [PMID: 15726661 DOI: 10.1002/hep.20569]
47. Raya-Sánchez JM, González-Reimers E, Rodríguez-Martín JM, Santolaria-Fernández F, Molina-Pérez M, Rodríguez-Moreno F, Martínez-Riera A. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15: 19-23 [PMID: 9426833 DOI: 10.1016/ S0741-8329(97)00082-7]
48. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol 2013; 304: H1585-H1597 [PMID: 23604713 DOI: 10.1152/ ajpheart.00096.2013]
49. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112: 19-27 [PMID: 18574041 DOI: 10.1182/blood-2008-01-077909]
50. Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 1801-12. e7 [PMID: 24793031 DOI: 10.1016/j.cgh.2014.04.026]
51. Saugel B, Lee M, Feichtinger S, Hapfelmeier A, Schmid RM, Siveke JT. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. J Thromb Thrombolysis 2015; 40: 54-60 [PMID: 25115839 DOI: 10.1007/s11239-014-1124-z]
52. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, Thursz M. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52: 1206-1210 [PMID: 12865283 DOI: 10.1136/gut.52.8.1206]
53. Poujol-Robert A, Boëlle PY, Poupon R, Robert A. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology 2004; 39: 1174-1175 [PMID: 15057924 DOI: 10.1002/hep.20166]
54. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003; 52: 404-409 [PMID: 12584224 DOI: 10.1136/ gut.52.3.404]
55. Xu Z, Westrick RJ, Shen YC, Eitzman DT. Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury. Thromb Haemost 2001; 85: 441-444 [PMID: 11307811]
56. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, Colombo M, Mannucci PM. An imbalance of provs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-2111 [PMID: 19706293 DOI: 10.1053/j.gastro.2009.08.045]
57. Tripodi A. Hemostasis abnormalities in cirrhosis. Curr Opin Hematol 2015; 22: 406-412 [PMID: 26203733 DOI: 10.1097/ MOH.0000000000000164]
58. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267-275 [PMID: 14961153 DOI: 10.1160/ TH03-05-0310]
59. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-540 [PMID: 17608762 DOI: 10.1111/j.1365-2141.2007.06688.x]
60. Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res 2008; 121: 675-680 [PMID: 17870147 DOI: 10.1016/j.thromres.2007.07.008]
61. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-237 [PMID: 12830006 DOI: 10.1053/jhep.2003.50277]
62. Leebeek FW, Rijken DC. The Fibrinolytic Status in Liver Diseases. Semin Thromb Hemost 2015; 41: 474-480 [PMID: 26049070 DOI: 10.1055/s-0035-1550437]
63. Adams DH, Burra P, Hubscher SG, Elias E, Newman W. Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology 1994; 19: 588-594 [PMID: 7509770 DOI: 10.1002/hep.1840190308]
64. Echeverría C, Montorfano I, Tapia P, Riedel C, Cabello-Verrugio C, Simon F. Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2. Infect Immun 2014; 82: 3678-3686 [PMID: 24935972 DOI: 10.1128/ IAI.02158-14]
65. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30: S302-S312 [PMID: 12004252 DOI: 10.1097/00003246-200210000-00049]
66. Salanova B, Choi M, Rolle S, Wellner M, Luft FC, Kettritz R. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils. J Biol Chem 2007; 282: 27960-27969 [PMID: 17644514 DOI: 10.1074/jbc.M704039200]
67. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694-1702 [PMID: 10688826]
68. Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, Heymes C, Letteron P, Elkrief L, Lebrec D, Valla D, Tedgui A, Moreau R, Boulanger CM. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology 2012; 143: 166-76.e6 [PMID: 22465620 DOI: 10.1053/j.gastro.2012.03.040]
69. Tapper EB, Robson SC, Malik R. Coagulopathy in cirrhosis-the role of the platelet in hemostasis. J Hepatol 2013; 59: 889-890 [PMID: 23669288 DOI: 10.1016/j.jhep.2013.03.040]
70. Rautou PE, Vion AC, Valla D, Boulanger CM. Circulating platelet derived microparticles are not increased in patients with cirrhosis. J Hepatol 2013; 59: 912 [PMID: 23816702 DOI: 10.1016/ j.jhep.2013.05.048]
71. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44: 440-445 [PMID: 16871542 DOI: 10.1002/hep.21266]
72. Ordinas A, Escolar G, Cirera I, Viñas M, Cobo F, Bosch J, Terés J, Rodés J. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996; 24: 1137-1142 [PMID: 8903388 DOI: 10.1002/ hep.510240526]
73. Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med 1967; 276: 1344-1348 [PMID: 6024565 DOI: 10.1056/NEJM196706152762403]
74. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724 [PMID: 22913681 DOI: 10.1056/NEJMoa1110709]
75. Wendum D, Prevot S, Poujol-Robert A, Rosmorduc O, Cabane J, Fouillard L, Flejou JF. [Liver involvement revealing systemic mastocytosis: report of two cases]. Gastroenterol Clin Biol 2004; 28: 80-83 [PMID: 15041817 DOI: 10.1016/ S0399-8320(04)94851-8]
76. Marra F, DeFranco R, Grappone C, Milani S, Pinzani M, Pellegrini G, Laffi G, Gentilini P. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 1998; 27: 462-471 [PMID: 9462645 DOI: 10.1002/hep.510270221]
77. Gaça MD, Zhou X, Benyon RC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol 2002; 36: 362-369 [PMID: 11867180 DOI: 10.1016/S0168-8278(01)00285-9]
78. Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 1995; 22: 780-787 [PMID: 7657283 DOI: 10.1002/ hep.1840220314]
79. Edwards RL, Levine JB, Green R, Duffy M, Mathews E, Brande W, Rickles FR. Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology 1987; 92: 329-337 [PMID: 3792769]
80. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 1989; 84: 1786-1793 [PMID: 2592560 DOI: 10.1172/ JCI114363]
81. Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, Burroughs AK. Coagulation and fibrosis in chronic liver disease. Gut 2008; 57: 1722-1727 [PMID: 19022928 DOI: 10.1136/gut.2008.150748]
82. Kitasato L, Yamaoka-Tojo M, Hashikata T, Ishii S, Kameda R, Shimohama T, Tojo T, Ako J. Factor Xa in mouse fibroblasts may induce fibrosis more than thrombin. Int Heart J 2014; 55: 357-361 [PMID: 24942638]
83. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247 [PMID: 7737629 DOI: 10.1002/ hep.1840210505]
84. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21: 1232-1237 [PMID: 7737628 DOI: 10.1002/ hep.1840210504]
85. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24: 99-106 [PMID: 15085490 DOI: 10.1055/s-2004-823104]
86. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C, Rosmorduc O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35: 1010-1021 [PMID: 11981751 DOI: 10.1053/jhep.2002.32524]
87. Moeller M, Thonig A, Pohl S, Ripoll C, Zipprich A. Hepatic arterial vasodilation is independent of portal hypertension in early stages of cirrhosis. PLoS One 2015; 10: e0121229 [PMID: 25793622 DOI: 10.1371/journal.pone.0121229]
88. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla DC. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61: 660-667 [PMID: 25284616 DOI: 10.1002/ hep.27546]
89. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D'Antò M, Capasso R, Zappia V, Ruggiero G. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005; 41: 995-1003 [PMID: 15834927 DOI: 10.1002/hep.20664]
90. Dik K, de Bruijne J, Takkenberg RB, Roelofs JJ, Tempelmans MJ, Dijkgraaf MG, Gelderblom HC, Reesink HW, Meijers JC, Jansen PL, Levi M. Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. Hepatol Res 2012; 42: 668-676 [PMID: 22385348 DOI: 10.1111/ j.1872-034X.2011.00963.x]
91. Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, Zelber-Sagi S, Rozovski U, Leshno M, Oren R. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol 2011; 17: 5007-5013 [PMID: 22174551 DOI: 10.3748/wjg.v17.i45.5007]
92. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60.e1-4 [PMID: 22819864 DOI: 10.1053/j.gastro.2012.07.018]
93. Shah B, Shah G. Antifibrotic effect of heparin on liver fibrosis model in rats. World J Gastrointest Pharmacol Ther 2012; 3: 86-92 [PMID: 23494756 DOI: 10.4292/wjgpt.v3.i6.86]
94. Jairath V, Burroughs AK. Anticoagulation in patients with liver cirrhosis: complication or therapeutic opportunity? Gut 2013; 62: 479-482 [PMID: 23300140 DOI: 10.1136/gutjnl-2012-303088]